Regulus Accounts Payable from 2010 to 2024

RGLS Stock  USD 1.63  0.02  1.24%   
Regulus Therapeutics Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable will likely drop to about 193.8 K in 2024. Accounts Payable is the amount Regulus Therapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Regulus Therapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2010-12-31
Previous Quarter
601 K
Current Value
792 K
Quarterly Volatility
1.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Regulus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regulus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 215.7 K, Interest Expense of 1.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 4.03, Dividend Yield of 0.0 or PTB Ratio of 1.75. Regulus financial statements analysis is a perfect complement when working with Regulus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Regulus Therapeutics Correlation against competitors.
For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.

Latest Regulus Therapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Regulus Therapeutics over the last few years. An accounting item on the balance sheet that represents Regulus Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Regulus Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Regulus Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regulus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Pretty Stable
   Accounts Payable   
       Timeline  

Regulus Accounts Payable Regression Statistics

Arithmetic Mean1,612,920
Geometric Mean864,475
Coefficient Of Variation115.74
Mean Deviation1,351,653
Median1,172,000
Standard Deviation1,866,820
Sample Variance3.5T
Range5.7M
R-Value(0.22)
Mean Square Error3.6T
R-Squared0.05
Significance0.43
Slope(91,387)
Total Sum of Squares48.8T

Regulus Accounts Payable History

2024193.8 K
2023204 K
2022175 K
2021285 K
2020535 K
20191.3 M
20181.7 M

About Regulus Therapeutics Financial Statements

Regulus Therapeutics shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Regulus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Regulus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Regulus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable204 K193.8 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Regulus Stock Analysis

When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.